Macroalbuminuric patients with type 2 diabetes and a recent acute coronary event who are treated with lixisenatide may experience a reduction in their urinary albumin-to-creatinine ratio, suggests an exploratory post-hoc analysis of the ELIXA trial.

Results of a post-hoc analysis suggest that the efficacy of lixisenatide is not compromised among patients with type 2 diabetes who have mild or moderate renal impairment.

Results of the placebo-controlled GetGoal-O trial suggest that adding lixisenatide to existing diabetes treatment improves glycemic control among nonfrail older patients with uncontrolled type 2 diabetes.

Read our quick round-up of the GetGoal trials of the daily injectable GLP-1 receptor agonist lixisenatide in people with type 2 diabetes.

See also: A quick guide to the SURPASS and SURMOUNT trials  (tirzepatide) A quick guide to the PIONEER trials  (oral semaglutide) A quick guide to the SUSTAIN trials  (semaglutide) A quick guide to the AWARD trials  (dulaglutide) A quick guide to the GetGoal trials  (lixisenatide) A quick guide to the LEAD trials  (liraglutide) A quick guide to the DURATION trials  (exenatide) STEP 1: Published Trial population: Obese or overweight people with related comorbidities, but not diabetes Comparator treatment: Placebo NCT03548935 The STEP 1 trial involved 1961 participants and was published in The New England Journal of Medicine in early 2021.

See also: A quick guide to the STEP trials (semaglutide for obesity) A quick guide to the PIONEER trials  (oral semaglutide) A quick guide to the SUSTAIN trials  (semaglutide) A quick guide to the AWARD trials  (dulaglutide) A quick guide to the GetGoal trials  (lixisenatide) A quick guide to the LEAD trials  (liraglutide) A quick guide to the DURATION trials  (exenatide) The SURPASS trials SURPASS-1: Published Trial population: Drug-naïve people with type 2 diabetes Comparator treatment: Placebo NCT03954834 SURPASS-1 tested tirzepatide at doses of 5, 10, and 15 mg, administered as a weekly subcutaneous injection, in people with type 2 diabetes who had elevated glycated hemoglobin (HbA1c) levels despite diet and exercise interventions.

See also: A quick guide to the SURPASS and SURMOUNT trials  (tirzepatide) A quick guide to the STEP trials (semaglutide for obesity) A quick guide to the PIONEER trials  (oral semaglutide) A quick guide to the SUSTAIN trials  (semaglutide) A quick guide to the AWARD trials  (dulaglutide) A quick guide to the GetGoal trials  (lixisenatide) A quick guide to the DURATION trials  (exenatide) The LEAD series LEAD-1: Published Trial population: People with type 2 diabetes on oral antidiabetic medications, all taking glimepiride Comparator treatments: Rosiglitazone, placebo NCT00318422 During 26 weeks of treatment, the average glycated hemoglobin (HbA1c) reduction was 1.1% with the highest dose of liraglutide used, of 1.8 mg/day.

See also: A quick guide to the SURPASS and SURMOUNT trials  (tirzepatide) A quick guide to the STEP trials (semaglutide for obesity) A quick guide to the PIONEER trials  (oral semaglutide) A quick guide to the SUSTAIN trials  (semaglutide) A quick guide to the AWARD trials  (dulaglutide) A quick guide to the GetGoal trials  (lixisenatide) A quick guide to the LEAD trials  (liraglutide) Trials of the original weekly formulation In its original form, microspheres of exenatide required reconstitution in an aqueous diluent before injection.

See also: A quick guide to the SURPASS and SURMOUNT trials  (tirzepatide) A quick guide to the STEP trials (semaglutide for obesity) A quick guide to the PIONEER trials  (oral semaglutide) A quick guide to the SUSTAIN trials  (semaglutide) A quick guide to the GetGoal trials  (lixisenatide) A quick guide to the LEAD trials  (liraglutide) A quick guide to the DURATION trials  (exenatide) AWARD-1: Published Trial population: People with type 2 diabetes taking metformin and pioglitazone Comparator treatments: Extended-release exenatide, placebo NCT01064687 The 976 AWARD-1 participants were stabilized on metformin and pioglitazone and then randomly assigned to receive dulaglutide at 1.5 or 0.75 mg/week, exenatide, or placebo.

medwireNews : Findings from the SoliMix trial indicate that a fixed-ratio combination (FRC) of basal insulin glargine and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi) may improve glycemic control with weight benefit compared with biphasic insulin aspart (BIAsp) 30 among people with suboptimally controlled type 2 diabetes on basal insulin.

In the IPTW analysis, the HRs for treatment modification with exenatide, liraglutide, and lixisenatide versus dulaglutide were 1.5, 1.2, and 2.0, respectively.

See also: A quick guide to the SURPASS and SURMOUNT trials  (tirzepatide) A quick guide to the STEP trials (semaglutide for obesity) A quick guide to the SUSTAIN trials  (semaglutide) A quick guide to the AWARD trials  (dulaglutide) A quick guide to the GetGoal trials  (lixisenatide) A quick guide to the LEAD trials  (liraglutide) A quick guide to the DURATION trials  (exenatide) PIONEER 1: Published Trial population: Medication-naïve people with type 2 diabetes Comparator treatment: Placebo As reported in Diabetes Care , 703 patients with glycated hemoglobin (HbA1c) levels between 7.0% and 9.5% (53 and 80 mmol/mol) were randomly assigned to receive daily oral semaglutide 3, 7, or 14 mg, or placebo.

The attenuated benefits relative to taking semaglutide as a first GLP-1 receptor agonist “makes perfectly logical sense because you would expect people having switched from dulaglutide, exenatide, lixisenatide, or liraglutide to have had some partial benefit from taking these drugs prior to switching to semaglutide,” said researcher Thomas Crabtree (Sandwell & West Birmingham Hospitals NHS Trust, UK).

Published trials ELIXA Medication: lixisenatide, daily injection N=6068; 100% with recent (≤180 days) acute coronary syndromes ELIXA was the first of these trials to publish, in 2015 in The New England Journal of Medicine .

See also: A quick guide to the SURPASS and SURMOUNT trials  (tirzepatide) A quick guide to the STEP trials (semaglutide for obesity) A quick guide to the PIONEER trials  (oral semaglutide) A quick guide to the AWARD trials  (dulaglutide) A quick guide to the GetGoal trials  (lixisenatide) A quick guide to the LEAD trials  (liraglutide) A quick guide to the DURATION trials  (exenatide) SUSTAIN 1: Published Trial population: type 2 diabetes Comparator treatment: placebo https://clinicaltrials.gov/ct2/show/NCT02054897 The SUSTAIN 1 findings were published in The Lancet Diabetes & Endocrinology in January 2017.

Recent CVOTs have demonstrated the CV safety of lixisenatide (ELIXA [3]) and once-weekly exenatide (EXSCEL [4]), and the CV benefit of liraglutide (LEADER [5]).

Use of a titratable, fixed-ratio combination of insulin glargine and the glucagon-like peptide 1 receptor agonist lixisenatide helps overweight patients with long-standing Type 2 diabetes to attain glycaemic control, shows a randomised trial.